Professional Development (
)
Feng Zhou has a proven track record in preclinical drug development, with expertise spanning oncology, immunology, and autoimmune diseases. He has led multiple cross-functional teams and managed various clinical and near-clinical projects, including small molecules and biologics like T-cell engagers and antibody-drug conjugates. His contributions include establishing in vitro pharmacology platforms, leading biomarker identification studies, and overseeing external collaborations with CROs and academic institutions. With a strong focus on leveraging cutting-edge technologies, he has been instrumental in identifying biomarkers, advancing drug candidates, and supporting clinical trial designs. 
Research Focus 
Feng Zhou’s research primarily focuses on cancer biology, immuno-oncology, and autoimmune diseases. He has contributed to the development of small molecules, PROTACs, antibody-drug conjugates (ADCs), and T-cell engagers (TCEs). His expertise lies in translating preclinical findings into clinical strategies, where he has successfully driven biomarker identification and drug efficacy studies. His extensive knowledge of tumor biology and immune mechanisms allows him to design innovative therapeutic strategies, making significant contributions to both oncology and immunology fields. 
Awards and Honors (
)
- Jiangsu Province Double Innovation Talent, 2020
- Zijinshan Talent Pioneer Program, Nanjing, 2021
- Industry Professor, China Pharmaceutical University, 2022
Publication Top Notes
- SCR‐7952, a highly selective MAT2A inhibitor (2024) – MedComm | Cited by: Not yet available
- Structure-based development and preclinical evaluation of SARS-CoV-2 3C-like protease inhibitor simnotrelvir (2023) – Nature Communications
| Cited by: Not yet available
- SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) (2023) – Breast Cancer Research
| Cited by: Not yet available
- Volitinib, a potent and highly selective c-Met inhibitor (2015) – Molecular Oncology | Cited by: 355
- Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) (2014) – Journal of Medicinal Chemistry
| Cited by: 147
- Post-transcriptional and post-translational regulation of PTEN by TGF-β1 (2009) – Journal of Cellular Biochemistry | Cited by: 52
Conclusion
Dr. Feng Zhou’s remarkable contributions to drug development, his strategic leadership in innovative research, and his collaborative spirit make him an outstanding candidate for the Best Researcher Award. His achievements not only highlight his individual excellence but also significantly contribute to the advancement of therapeutic strategies in the biomedical field, paving the way for future breakthroughs in medicine. Awarding him this recognition would not only honor his past accomplishments but also encourage further advancements in drug discovery and development.